Trump Eyes 100% Tariffs on Pharma & Metals

The United States has implemented significant adjustments to its tariff structures, impacting both pharmaceutical imports and metals. Under new directives, foreign pharmaceutical manufacturers could face tariffs as high as 100% if they do not agree to reduce drug prices or shift production to the US. Companies complying partially will face a 20% duty, while full relocation or price reduction negates tariffs. Trade agreements with several countries will cap tariffs at 15%, and a separate deal with the UK ensures zero tariffs for three years under specific conditions.

In parallel, revisions have been made to tariffs on steel, aluminum, and copper. Duties on many derivative products have been reduced to 25%, and tariffs on items with minimal metal content have been eliminated. However, a 50% duty remains on core commodity imports of these metals. The calculation method for these tariffs has also shifted from import value to US sales price. These changes are a strategic reset for global trade, intended to bolster domestic manufacturing and secure international concessions, though industry groups have expressed concerns about potential impacts on healthcare costs and manufacturing sectors.